Duncker Streett & Co’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Duncker Streett & Co’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-160	Closed	-$5K	–	616
2017 Q2	$5K	Hold	160	–	–	﹤0.01%	571
2017 Q1	$5K	Hold	160	–	–	﹤0.01%	583
2016 Q4	$6K	Hold	160	–	–	﹤0.01%	565
2016 Q3	$7K	Hold	160	–	–	﹤0.01%	540
2016 Q2	$8K	Hold	160	–	–	﹤0.01%	523
2016 Q1	$9K	Hold	160	–	–	﹤0.01%	520
2015 Q4	$11K	Hold	160	–	–	﹤0.01%	509
2015 Q3	$9K	Hold	160	–	–	﹤0.01%	525
2015 Q2	$9K	Hold	160	–	–	﹤0.01%	536
2015 Q1	$10K	Hold	160	–	–	﹤0.01%	528
2014 Q4	$9K	Hold	160	–	–	﹤0.01%	529
2014 Q3	$9K	Hold	160	–	–	﹤0.01%	530
2014 Q2	$8K	Hold	160	–	–	﹤0.01%	542
2014 Q1	$8K	Hold	160	–	–	﹤0.01%	516
2013 Q4	$6K	Sell	160 -250	-61%	-$9.84K	﹤0.01%	515
2013 Q3	$15K	Sell	410 -250	-38%	-$9.75K	0.01%	443
2013 Q2	$26K	Buy	+660	New	+$25.7K	0.01%	402

Other funds holding TEVA

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Duncker Streett & Co's TEVA Position: Q3 2017 in Review

Duncker Streett & Co sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2017, closing a stake of 160 shares — an estimated $5K sold.

Duncker Streett & Co first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $26K in Q2 2013. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Duncker Streett & Co reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2017 after selling out during the quarter.
Duncker Streett & Co sold 160 Teva Pharmaceutical Industries Limited shares in Q3 2017, an estimated $5K.
Duncker Streett & Co first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and held it in 17 quarters.
Duncker Streett & Co's Teva Pharmaceutical Industries Limited position peaked at $26K in Q2 2013.
537 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2017.

Based on Duncker Streett & Co's 13F filing for Q3 2017, filed 25 Oct 2017.